A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
Julie E. Martin(National Institutes of Health), Barney S. Graham(National Institutes of Health), Mary E. Enama(National Institutes of Health), Brenda Larkin(National Institutes of Health), Martha Nason(National Institutes of Health), Mark K. Louder(Henry M. Jackson Foundation), Ingelise J. Gordon(National Institute of Allergy and Infectious Diseases), Gary J. Nabel(National Institutes of Health), Robert T. Bailer(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Leatrice Vogel(National Institutes of Health), Phillip L. Gomez(National Institutes of Health), Mario Roederer(National Institutes of Health), Charla Andrews(National Institutes of Health), LaSonji A. Holman(National Institutes of Health), Richard A. Koup(Aaron Diamond AIDS Research Center)
Cited by 274
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
|Science|2010|1.8k
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
|Journal of Immunological Methods|2003|1.6k